BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.